Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

Neurology

Volumn 87, Issue 13, 2016, Pages 1329-1336

  Rohrer, Jonathan D ^a   Woollacott, Ione O C ^a   Dick, Katrina M ^a   Brotherhood, Emilie ^a   Gordon, Elizabeth ^a   Fellows, Alexander ^a   Toombs, Jamie ^a   Druyeh, Ronald ^a   Cardoso, M Jorge ^a,b   Ourselin, Sebastien ^a,b   Nicholas, Jennifer M ^a,c   Norgren, Niklas ^d   Mead, Simon ^a   Andreasson, Ulf ^e   Blennow, Kaj ^e   Schott, Jonathan M ^a   Fox, Nick C ^a   Warren, Jason D ^a   Zetterberg, Henrik ^a,e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UmanDiagnostics AB   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT PROTEIN; PROGRANULIN; TAU PROTEIN; BIOLOGICAL MARKER; C9ORF72 PROTEIN, HUMAN; GRN PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; NEUROFILAMENT PROTEIN L; PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN SIZE; CHROMOSOME 9 OPEN READING FRAME 72; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MICROTUBULE ASSOCIATED PROTEIN TAU GENE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OPEN READING FRAME; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGRANULIN GENE; PROTEIN BLOOD LEVEL; ATROPHY; BLOOD; DIAGNOSTIC IMAGING; FOLLOW UP; FRONTAL LOBE; GENETICS; PSYCHOMETRY; SEVERITY OF ILLNESS INDEX;

AGED; APHASIA, PRIMARY PROGRESSIVE; ATROPHY; BIOMARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRONTAL LOBE; FRONTOTEMPORAL DEMENTIA; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROFILAMENT PROTEINS; PROTEINS; PSYCHOMETRICS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84988910596     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003154     Document Type: Article

References (35)

1. Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011; 82: 476-486
2. Warren JD, Rohrer JD, Rossor MN. Clinical review: frontotemporal dementia. BMJ 2013; 347: f4827
3. Rohrer JD, Zetterberg H. Biomarkers in frontotemporal dementia. Biomark Med 2014; 8: 519-521
4. Rosengren LE, Karlsson JE, Sjögren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999; 52: 1090-1093
5. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-1964
6. Brettschneider J, Petzold A, Schottle D, Claus A, Riepe M, Tumani H. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer?s disease. Dement Geriatr Cogn Disord 2006; 21: 291-295
7. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007; 4: 185-194
8. Pijnenburg YA, Janssen JC, Schoonenboom NS, et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer?s disease and controls. Dement Geriatr Cogn Disord 2007; 23: 225-230
9. De Jong D, Jansen RW, Pijnenburg YA, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 2007; 78: 936-938
10. Landqvist Waldö M, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 2013; 13: 54
11. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014; 75: 116-126
12. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41
13. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012; 19: 1561-1567
14. Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015; 84: 2247-2257
15. Rissin DM, Kan CW, Campbell TG, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010; 28: 595-599
16. Kuhle J, Barro C, Andreasson U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med Epub 2016 Apr 12. doi: 10.1515/cclm-2015-1195
17. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477
18. Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 131-146
19. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
20. Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation 1999
21. Warrington EK. Manual for the Recognition Memory Test for Words and Faces. Windsor, UK: NFER-Nelson 1984
22. McKenna P, Warrington EK. Testing for nominal dysphasia. J Neurol Neurosurg Psychiatry 1980; 43: 781-788
23. Jackson M, Warrington EK. Arithmetic skills in patients with unilateral cerebral lesions. Cortex 1986; 22: 611-620
24. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-kefs). San Antonio, TX: The Psychological Corporation 2001
25. Folstein M, Folstein S, McHugh P. The Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198
26. Freeborough PA, Fox NC, Kitney RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997; 53: 15-25
27. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997; 16: 623-629
28. Cardoso MJ, Modat M, Wolz R, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans Med Imaging 2015; 34: 1976-1988
29. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015; 14: 253-262
30. Disanto G, Adiutori R, Dobson R, et al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2016; 87: 126-129
31. Kuhle J, Gaiottino J, Leppert D, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 2015; 86: 273-279
32. Al Nimer F, Thelin E, Nyström H, et al. Comparative assessment of the prognostic value of biomarkers in traumatic brain injury reveals an independent role for serum levels of neurofilament light. PLoS One 2015; 10: e0132177
33. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012; 135: 736-750
34. Knopman DS, Kramer JH, Boeve BF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain 2008; 131: 2957-2968
35. Mioshi E, Hsieh S, Savage S, Hornberger M, Hodges JR. Clinical staging and disease progression in frontotemporal dementia. Neurology 2010; 74: 1591-1597